compounded glp-1 ban FDA on Drugs: What to Know FDA issued 25 warning letters

demonstrated GLP-1 RAs broadly suppress perception of all five basic taste modalities, potentially mediated through brainstem GLP-1Rs and vagally mediated pathways 44

Injection Therapy: Administer under professional supervision for targeted skin and tissue repair

Published human outcome data are too limited and poorly reported to confirm benefits for digestive diseases, ulcers, inflammatory bowel disease, or gut healing

Start by injecting 1ml/cc per injection once per week

GLP-1 patches remain primarily investigational, with limited FDA-approved options currently available

Given widespread, unofficial use, reporting appears limited